TauC3 Biologics

Executive Summary

TauC3 Biologics is a UK-based private biotechnology company advancing precision immunotherapies for neurodegenerative diseases, specifically targeting tauopathies such as tau-related frontotemporal dementia (FTD-tau) and progressive supranuclear palsy (PSP). Founded in 2018, the company leverages proprietary antibody technology to halt the spread of tau pathology and neuronal destruction. With a Phase 2 clinical program underway, TauC3 aims to address the significant unmet need in these rapidly progressive conditions, where no disease-modifying therapies are currently approved. The company's approach targets specific conformations of tau protein, potentially offering improved efficacy and safety over earlier tau-directed therapies.

Upcoming Catalysts (preview)

• Q1 2027Phase 2 interim data readout for FTD-tau40% success
• Q3 2026Strategic partnership or licensing deal for PSP program30% success
• Q4 2026Series B or additional financing round80% success